Clinical Trial Update: The Study of Drotrecogin Alfa (Activated) in Adult Patients With Severe Sepsis at a Low Risk of Death [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating drotrecogin alfa (activated) in adults with severe sepsis at low risk of death has been completed. The sponsor is Eli Lilly …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis

Drugs mentioned

• Drotrecogin alfa (activated) (drotrecogin alfa (activated))

Snippet

Sponsor: Eli Lilly and Company | Conditions: Sepsis | Phase 3 | Status: COMPLETED